Analytica Limited (ASX:ALT) has received clearance from the Australian Therapeutic Goods Administration for the expanded clinical indication for its PeriCoach System to assist in the conservative treatment of Pelvic Organ Prolapse (POP).
The PeriCoach system with its patent protected force sensing technology assists women to properly perform pelvic floor exercises.
The expanded clinical indication for PeriCoach now includes targeted resolution of symptoms for mild to moderate POP, urinary incontinence and sexual wellness.
Let's face it: there is strength in numbers. Support gives us motivation, determination, and is what propels us to be successful. The #PeriCoach #8WeekChallenge will help you meet your goals with just 5 minutes a day. Join #TeamPeriCoach https://t.co/575qCpALIU pic.twitter.com/yHrbBVa4oH— PeriCoach AUS (@PeriCoach) April 23, 2018
Pelvic organ prolapse is a common and serious condition
Data suggests that 50% of women that have given birth have some degree of POP and half of women over 50 complain of prolapse symptoms.
Estimates state women have a lifetime risk of up to 12% of undergoing a surgical intervention, with a re-operation rate of nearly 20%.
Each surgical intervention in the U.S. is estimated to cost between USD$10,000- USD$20,000.
As the population continues to age and awareness of the condition grows, it is projected that the number of women with POP will increase up to 46%.
Potential sale of the technology to a multinational
Analytica chairman Dr Michael Monsour said: “This clearance from the TGA is significant in that the PeriCoach system is indicated for the most common conditions stemming from a weak pelvic floor: urinary incontinence, sexual wellness, and pelvic organ prolapse.
“No other system on the market has this capability.
“This additional capability adds substantial value and progresses the sale of the company and PeriCoach system to a multinational”.